Claims for Patent: 9,517,235

Summary for Patent: 9,517,235

Title:	Methods for treating antipsychotic-induced weight gain
Abstract:	The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
Inventor(s):	Daniel Deaver, Mark Todtenkopf
Assignee:	Alkermes Pharma Ireland Ltd
Application Number:	US14/813,260
Patent Claims:	1. A method of reducing diseases or disorders associated with the adverse metabolic profile of olanzapine by administering to a patient in need 10 thereof an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof. 2. The method according to claim 1, wherein said adverse metabolic effects comprise an increase in abdominal fat distribution, serum glucose levels, triglyceride levels or high density cholesterol. 3. The method of claim 1, wherein said disease or disorder is diabetes. 4. The method of claim 1, wherein said diseases or disorders are cardiovascular disorders. 5. The method of claim 1, wherein the disease or disorder is obesity. 6. The method of claim 1, wherein the disease or disorder is hypertension. 7. A method of lowering circulating ghrelin levels in a patient in need thereof, comprising administering to said patient an effective amount of the compound of formula: or a pharmaceutically acceptable salt thereof. 8. A method of lowering circulating ghrelin levels in a patient in need thereof, comprising administering to said patient an effective amount of the compound of formula: or a pharmaceutically acceptable salt thereof, wherein said ghrelin level is increased by the administration of an atypical antipsychotic. 9. The method according to claim 8, wherein said atypical antipsychotic is olanzapine. 10. A method of lowering ghrelin levels in gastrointestinal tracts of a patient in need thereof, comprising administering to said patient an effective amount of the compound of formula: or a pharmaceutically acceptable salt thereof. 11. A method of lowering ghrelin levels in gastrointestinal tracts of a patient in need thereof, comprising administering to said patient an effective amount of the compound of formula: or a pharmaceutically acceptable salt thereof, wherein said ghrelin level is increased by the administration of an atypical antipsychotic. 12. The method according to claim 11, wherein said atypical antipsychotic is olanzapine.